Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Yervoy

- PMLiVE

AbbVie’s Elahere granted full FDA approval for previously-treated ovarian cancer

The company recently gained access to the therapy through its $10.1bn acquisition of ImmunoGen

- PMLiVE

AstraZeneca’s Tagrisso combination shows promising overall survival trend in phase 3 lung cancer study

An estimated 2.4 million people globally are diagnosed with lung cancer every year

- PMLiVE

Bristol Myers Squibb announces EC approval for multiple myeloma therapy Abecma

Approximately 50,000 cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

Researchers reveal imaging technology could help diagnose and treat bowel cancer

Affecting over 250,000 people, bowel cancer is the fourth most common cancer in the UK

- PMLiVE

AstraZeneca to acquire Fusion Pharmaceuticals in deal worth $2.4bn

The transaction includes a potential new treatment for metastatic castration-resistant prostate cancer

- PMLiVE

AstraZeneca shares positive late-stage results for Imfinzi and Lynparza in endometrial cancer

The incidence of endometrial cancer is expected to increase by approximately 61% in 2050

- PMLiVE

GSK’s Jemperli regimens demonstrate potential for wider endometrial cancer use

Approximately 417,000 new cases of endometrial cancer are reported globally every year

- PMLiVE

Merck presents positive phase 3 data for Keytruda plus CRT in advanced cervical cancer

According to WHO, cervical cancer is the fourth most common cancer in women globally

- PMLiVE

New technique enables study of immune response to cancer using archived tissue samples

FUME-TCRseq was shown to successfully read formalin-fixed paraffin-embedded tissue samples

- PMLiVE

Pfizer’s Adcetris combination shows promise in phase 3 large B-cell lymphoma study

The aggressive blood cancer affects more than 25,000 people in the US every year

- PMLiVE

Ipsen’s Cabometyx and BMS’ Opdivo recommended by NICE for advanced kidney cancer

The decision could benefit approximately 2,287 patients with renal cell carcinoma annually

- PMLiVE

The Power Dynamics of Women and Cancer

Women, Power, and Cancer: a Lancet commission, studied the interaction of women and cancer through a social justice and equity lens. What does ‘power’ mean when it comes to cancer...

Medscape Education Global

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links